Valuation: Incyte Corporation

Market Cap 2.44TCr 2.12TCr 1.99TCr 1.81TCr 3.41TCr 2,33200Cr 3.46TCr 23TCr 9.12TCr 1,16700Cr 9.17TCr 8.97TCr 3,89300Cr P/E 2026 *
53.1x
P/E 2027 * 16.8x
Enterprise Value 2.02TCr 1.75TCr 1.64TCr 1.5TCr 2.81TCr 1,92600Cr 2.86TCr 19TCr 7.54TCr 96TCr 7.58TCr 7.41TCr 3,21600Cr EV / Sales 2026 *
3.4x
EV / Sales 2027 * 2.98x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day-0.21%
1 week+1.81%
Current month+0.84%
1 month+5.51%
3 months+21.96%
6 months+19.21%
Current year+22.02%
1 week 118.88
Extreme 118.88
122.69
1 month 110.56
Extreme 110.56
132.6
Current year 89.25
Extreme 89.25
132.6
1 year 81.09
Extreme 81.09
132.6
3 years 50.27
Extreme 50.27
132.6
5 years 50.27
Extreme 50.27
132.6
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Date Insider Type Main position Quantity % Market Cap.
05/08/26 Fiscal year

EVP & Chief Scientific Officer

6,621 0.0033%
05/08/26 Sell

Chairperson

-10,640 0.0052%
03/08/26 Fiscal year

EVP & Chief Scientific Officer

18,165 0.0090%
Change 5-day change 1-year change 3-year change Capi.($)
-0.21%+1.81%+40.38%+82.80% 2.44TCr
+1.00%+4.39%+43.53%-0.12% 8.05TCr
+0.97%+3.30%-2.19%+26.99% 5.11TCr
-1.22%-2.62%+15.13%+167.13% 4.82TCr
-0.74%+3.26%-49.46%-48.10% 4.65TCr
+0.85%+2.12%+55.82%-23.03% 3.11TCr
-0.03%+18.18%+136.71%-37.28% 2.54TCr
-0.63%-0.47%-1.67%+191.36% 2.11TCr
-3.14%-1.92%+61.19%+161.38% 1.59TCr
+0.85%+0.63%+62.89%+111.21% 1.63TCr
Average -0.25%+3.16%+36.23%+63.23% 3.6TCr
Weighted average by Cap. +0.01%+3.01%+27.68%+44.27%

Financials

2026 *2027 *
Net sales 594.27Cr 515.11Cr 482.88Cr 440.29Cr 828.45Cr 57TCr 841.72Cr 5.69TCr 2.22TCr 28TCr 2.23TCr 2.18TCr 95TCr 625.33Cr 542.04Cr 508.12Cr 463.31Cr 871.76Cr 60TCr 885.72Cr 5.98TCr 2.34TCr 30TCr 2.35TCr 2.3TCr 1LCr
Net income 47Cr 41Cr 38Cr 35Cr 66Cr 4.5TCr 67Cr 451.31Cr 176.19Cr 2.25TCr 177.09Cr 173.26Cr 7.52TCr 147.35Cr 127.72Cr 119.73Cr 109.17Cr 205.41Cr 14TCr 208.7Cr 1.41TCr 550.37Cr 7.04TCr 553.19Cr 541.21Cr 23TCr
Net Debt -424.92Cr -368.32Cr -345.27Cr -314.82Cr -592.37Cr -41TCr -601.86Cr -4.07TCr -1.59TCr -20TCr -1.6TCr -1.56TCr -68TCr -581.22Cr -503.8Cr -472.27Cr -430.62Cr -810.26Cr -55TCr -823.24Cr -5.56TCr -2.17TCr -28TCr -2.18TCr -2.13TCr -93TCr
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
13/26/13 $120.52 -0.21% 8,29,464
12/26/12 $120.77 -0.25% 10,55,267
11/26/11 $121.07 -0.39% 10,80,064
10/26/10 $121.55 +0.82% 13,52,384
07/26/07 $120.56 +1.84% 15,40,373
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
120.52USD
Average target price
125.17USD
Spread / Average Target
+3.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock